ACC deletion has been shown to inhibit PPARα expression, which enhances LPL activity, and therefore, in order to avoid adverse effects, knockdown of ACC to treat NAFLD may need to be coupled with PPARα agonists. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.